Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 27, 2020, BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") held its 2020 Annual Meeting of Stockholders (the "Annual Meeting"). A total of 180,760,753 shares of common stock were entitled to vote as of March 30, 2020, the record date for the Annual Meeting. There were 164,141,017 shares of common stock present in person or represented by proxy at the Annual Meeting, at which the stockholders were asked to vote on three proposals, each of which is described in more detail in BioMarin's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 14, 2020 (the "Proxy Statement"). Set forth below are the matters acted upon by the stockholders, and the final voting results of each such proposal.

Proposal No. 1: Election of Directors



                                                                     Broker
Directors Elected                 Vote For          Withheld        Non-Votes
Jean-Jacques Bienaimé             148,356,194        7,402,776       8,382,047
Elizabeth McKee Anderson          155,409,655          349,315       8,382,047
Willard Dere, M.D.                154,930,505          828,465       8,382,047
Michael Grey                      145,140,776       10,618,194       8,382,047
Elaine J. Heron, Ph.D.            151,292,610        4,466,360       8,382,047
Robert J. Hombach                 154,479,935        1,279,035       8,382,047
V. Bryan Lawlis, Ph.D.            152,651,613        3,107,357       8,382,047
Richard A. Meier                  153,060,357        2,698,613       8,382,047
David E.I. Pyott, M.D. (Hon.)     154,499,783        1,259,187       8,382,047
Dennis J. Slamon, M.D., Ph.D.     155,216,209          542,761       8,382,047

Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner, until the director's death, resignation or removal.

Proposal No. 2: Ratification of the Selection of Independent Registered Public Accounting Firm

The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending December 31, 2020, as set forth in the Proxy Statement, received the following votes:



    For        Against    Abstain
162,933,181   1,109,134   98,702

Based on the votes set forth above, BioMarin's stockholders ratified the selection of KPMG LLP as BioMarin's independent registered public accounting firm to serve for the year ending December 31, 2020.

Proposal No. 3: Advisory Vote on the Compensation of BioMarin's Named Executive Officers

The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the following votes:



                                     Broker
    For        Against    Abstain   Non-Votes
149,206,456   5,821,456   731,058   8,382,047

Based on the votes set forth above, BioMarin's stockholders approved, on an advisory basis, the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses